6589 Taikang Bio's Biosimilar Drug 'EIRGASUN vial 420 mg' Approved for National Health Insurance Coverage by NHIA

Date of Announcement: 2026/05/16 Date of Occurrence: 2026/05/15 Time of Occurrence: 14:19:34 Company Code: 6589 Company Name: Taikang Bio Subject: Our company's biosimilar drug 'EIRGASUN vial 420 mg' has been approved for inclusion in National Health Insurance coverage by the National Health Insurance Administration, Ministry of Health and Welfare. Applicable clause: Article 51 Date of event: 2026/05/15 Explanation: 1. Date of occurrence of the event: 2026/05/15 2. Company name: Taikang Biotechnology Co., Ltd. 3. Relationship with the company (please enter 'our company' or 'subsidiary'): Our company 4. Mutual shareholding ratio: Not applicable 5. Reason for occurrence: (1) Our company's biosimilar drug 'EIRGASUN vial 420 mg', used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric cancer, has been approved for inclusion in the National Health Insurance coverage by the National Health Insurance Administration, Ministry of Health and Welfare. The approved payment price is NT$24,240 per vial, effective from June 1, 2026. (2) According to the 2024 medical order declaration data published by the National Health Insurance Administration, the total annual declaration volume for Trastuzumab 420mg to 440mg specifications reached 30,942 vials. 6. Countermeasures: Release of material information. 7. Other matters that should be stated (if the subject of the event or resolution is a public company or above, this material information also complies with Article 7, Paragraph 9 of the Enforcement Rules of the Securities Exchange Act regarding matters that have a significant impact on shareholders' equity or securities prices): None